
Eli Lilly and Company (NYSE: LLY) has been one of the best-performing stocks outside of the AI-enhanced Magnificent 7 stocks over the past 12 months. The company is the leader in the GLP-1 market, which is transforming the management of type 2 diabetes and the obesity market.
LLY stock is up 10% in the last month on news that the U.S. Food & Drug Administration (FDA) indicated it may fast-track the company’s oral GLP-1 candidate.